Molybdenum cofactor deficiency and therapy
Over the last two decades we have developed the first causative therapy for molybdenum cofactor deficiency type A. We continue to deepen our understand on the molecular basis of molybdenum cofactor deficiency and work on the development on novel therapies (MOCS2, type B)